EUVIMEDEUVIMED entdecken
Crossref

Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America: A Report From the LACOG Sarcoma Group

Douglas Dias E Silva, Bruna Bianca Lopes David iD, Veridiana Pires de Camargo iD, Renee Zon Filipi, María Lucila González Donna, Juan Carlos Haro Varas iD, Rodrigo Ramella Munhoz iD, Maycos L Zapata iD, Cicero Luiz Cunha Martins iD, Matias Chacon, Rafael Schmerling iD, Reynaldo Jesus Garcia iD und 1 weitere

JCO Global Oncology · 2025

DOI: 10.1200/go.24.00239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Douglas Dias E Silva und 12 weiteren Autor:innen. Beteiligte Einrichtung: Latin American Cooperative Oncology Group, Porto Alegre, Brazil. Hauptthemen laut MEDLINE: Sarcoma, Drug Approval, Rare Diseases, Health Policy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The availability of drugs and national public policies for patients with rare cancers, including sarcomas, varies in different parts of the world. METHODS In this manuscript, we have conducted a comprehensive analysis to evaluate rare cancer policies in Latin American countries' national policy documents. Additionally, we have reviewed the approvals for sarcoma drugs in selected Latin American countries and compared them with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals. RESULTS The documents reviewed showed a lack of explicit focus on rare cancers, with no mention in 70% of the countries analyzed. Drug approval data reveal that in the last 15 years, the FDA and EMA have approved 19 and 13 drugs for sarcoma, whereas their Latin American counterparts, namely ANVISA, ANMAT, and COFEPRIS, approved six, eight, and seven drugs, respectively. CONCLUSION Our data suggest that improving rare cancer and sarcoma care in Latin America requires enhanced collaboration for better rare cancer policies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaDrug ApprovalRare DiseasesHealth PolicyAntineoplastic AgentsHumansLatin AmericaUnited States

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Latin American Cooperative Oncology Group, Porto Alegre, Brazil.
  • Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Oncoclínicas, Rio de Janeiro, Brazil.
  • Instituto Nacional do Câncer (INCA), Rio de Janeiro, Brazil.
  • Hospital Beneficência Portuguesa, São Paulo, Brazil.
  • Instituto Nacional del Cancer Paraguay, Capiata, Paraguay.

ORCID-Profile: Bruna Bianca Lopes David, Veridiana Pires de Camargo, Juan Carlos Haro Varas, Rodrigo Ramella Munhoz, Maycos L Zapata, Cicero Luiz Cunha Martins, Rafael Schmerling, Reynaldo Jesus Garcia, Roberto Carmagnani Pestana

Zitieren

APA

Dias E Silva, D., Lopes David, B. B., Pires de Camargo, V., Zon Filipi, R., González Donna, M. L., Haro Varas, J. C., Ramella Munhoz, R., Zapata, M. L., Cunha Martins, C. L., Chacon, M., Schmerling, R., Jesus Garcia, R., & Carmagnani Pestana, R. (2025). Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America: A Report From the LACOG Sarcoma Group. JCO Global Oncology. https://doi.org/10.1200/go.24.00239

Vancouver

Dias E Silva D, Lopes David BB, Pires de Camargo V, Zon Filipi R, González Donna ML, Haro Varas JC, et al. Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America: A Report From the LACOG Sarcoma Group. JCO Global Oncology. 2025. doi:10.1200/go.24.00239

BibTeX
@article{DiasESilva2025,
  author = {Dias E Silva, Douglas and Lopes David, Bruna Bianca and Pires de Camargo, Veridiana and Zon Filipi, Renee and González Donna, María Lucila and Haro Varas, Juan Carlos and Ramella Munhoz, Rodrigo and Zapata, Maycos L and Cunha Martins, Cicero Luiz and Chacon, Matias and Schmerling, Rafael and Jesus Garcia, Reynaldo and Carmagnani Pestana, Roberto},
  title = {Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America: A Report From the LACOG Sarcoma Group},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go.24.00239}
}
Kostenlos starten →